Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 6, 2001, Pages 461-466

  Amtmann, Eberhard ^a   Zöller, Margot ^a   Wesch, Horst ^a   Schilling, Gerhard ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Platinum compound; Prodrug

Indexed keywords

CISPLATIN; PLASMID DNA; PLATINUM COMPLEX; SULFUR DERIVATIVE; THIOPLATIN; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; INTESTINE INJURY; KIDNEY ISCHEMIA; LEUKOCYTE COUNT; LEUKOPENIA; LIPOPHILICITY; LUNG SMALL CELL CANCER; MOUSE; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CARCINOMA, SMALL CELL; CISPLATIN; COLORECTAL NEOPLASMS; CROSS-LINKING REAGENTS; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; LEUKEMIA L1210; LUNG NEOPLASMS; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; SARCOMA 180; SULFUR COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0035024775     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000261     Document Type: Article

References (13)

1. 1. Hollis LS (1991) In: Howell SB (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum Press, New York, p 115
2. 2. Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522-1534
3. 3. Warburg O (1926) Über den Stoffwechsel der Tumoren. Springer, Berlin
4. 4. Gerweck LE (1998) Tumor pH: implications for treatment and novel drug design. Semin Radiat Oncol 8:176-182
5. 5. Knox RJ, Friedlos F, Lydall DA (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972-1979
6. 6. Mong S, Daskal Y, Prestayko AW, Crooke ST (1981) DNA supercoiling, shortening, and induction of single-strand regions by cis-diamminedichloroplatinum(II). Cancer Res 41:4020-4026
7. 7. Scovell WM, Kroos LR (1982) Cis-and trans-diamminedichloroplatinum(II) binding products different tertiary structural changes on SV40 DNA. Biochem Biophys Res Commun 104:1597-1603
8. 8. Roberts JJ, Thomson AJ (1979) The mechanism of action of antitumor platinum compounds. Prog Nucleic Acids Res Mol Biol 22:71-133
9. 9. von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM (1979) Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63:1527-1531
10. 10. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum I. Cancer Chemother Pharmacol 9:140-147
11. 11. Johnson NP, Hoeschele JD, Rahn RO (1980) Kinetic analysis of the in vitro binding of radioactive cis-and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 30: 151-169
12. 12. Jones MM, Basinger MA, Holscher MA (1992) Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. Fundam Appl Toxicol 18:181-181
13. 13. Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR (1992) Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Cancer Res 52:6188-6193